M
M.L.C. Hagemans
Researcher at Erasmus University Rotterdam
Publications - 32
Citations - 2186
M.L.C. Hagemans is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Enzyme replacement therapy & Glycogen storage disease type II. The author has an hindex of 21, co-authored 32 publications receiving 2024 citations. Previous affiliations of M.L.C. Hagemans include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients
M.L.C. Hagemans,Leon P. F. Winkel,P.A. van Doorn,W. J. C. Hop,M. C. B. Loonen,A. J. J. Reuser,A.T. van der Ploeg +6 more
TL;DR: It is concluded that early manifestations in childhood require proper attention to prevent unnecessary delay of the diagnosis and the follow-up of patients with late-onset Pompe's disease should focus on respiratory and limb-girdle muscle function, the capacity to perform daily activities, and the presentation of fatigue and pain.
Journal ArticleDOI
The natural course of non-classic Pompe's disease; a review of 225 published cases.
Leon P. F. Winkel,M.L.C. Hagemans,Pieter A. van Doorn,M Christa B Loonen,Wim J C Hop,Arnold J. J. Reuser,Ans T. van der Ploeg +6 more
TL;DR: The natural course of cases not fitting the definition of classic infantile Pompe’s disease, a review of 109 reports including 225 cases shows a continuous spectrum of phenotypes, with patients with a later onset of symptoms seemed to have a better prognosis.
Journal ArticleDOI
Disease severity in children and adults with Pompe disease related to age and disease duration
M.L.C. Hagemans,Leon P. F. Winkel,Wim C. J. Hop,A. J. J. Reuser,P.A. van Doorn,A.T. van der Ploeg +5 more
TL;DR: The patient group under age 15 included a subgroup with a more severe and rapid course of the disease, which requires more intensive follow-up and early intervention, before irreversible damage has occurred.
Journal ArticleDOI
Broad spectrum of Pompe disease in patients with the same c.-32-13T→G haplotype
Marian A. Kroos,Robert J. Pomponio,M.L.C. Hagemans,J. L. M. Keulemans,Maureen G. Phipps,M. DeRiso,Rachel Palmer,M.G.E.M. Ausems,N.A.M.E. van der Beek,O. P. van Diggelen,D. J. J. Halley,A.T. van der Ploeg,Arnold J. J. Reuser +12 more
TL;DR: Patients with the same c.-32-13T→G haplotype may manifest first symptoms at different ages, indicating that secondary factors may substantially influence the clinical course of patients with this mutation.
Journal ArticleDOI
Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study
Nadine A. M. E. van der Beek,Nadine A. M. E. van der Beek,Juna M. de Vries,Juna M. de Vries,M.L.C. Hagemans,Wim C. J. Hop,Marian A. Kroos,John H. J. Wokke,Marianne de Visser,Baziel G.M. van Engelen,Jan B. M. Kuks,Anneke J. van der Kooi,Nicolette C. Notermans,Karin G. Faber,Jan J.G.M. Verschuuren,Arnold J. J. Reuser,Ans T. van der Ploeg,Pieter A. van Doorn +17 more
TL;DR: Recognizing patterns of common and less familiar characteristics in adults with Pompe disease facilitates timely diagnosis and aid in deciding whether to initiate enzyme replacement therapy, or when, and stand out as predictors of rapid disease progression.